No. As of 20 November 2026, daraxonrasib, the daily pancreatic cancer pill behind this week’s “breakthrough” headlines, is not licensed in the UK and cannot be prescribed on the NHS. The only way UK patients can currently receive it is through a clinical trial. It has been approved in the United States and the European Union, but only for people whose cancer has already spread and been treated, and those approvals do not apply here.
That gap between the excitement and what a patient can actually get is why so many people are asking the same question today. Here is what the new results show, why the drug is not yet available in Britain, and what has to happen before it could be.
What did the new daraxonrasib trial find?
The latest results come from an early-stage (phase 1/2) study run by the drug’s maker, Revolution Medicines, and were presented at the EORTC-NCI-AACR cancer symposium in Barcelona. Sixty-one people who had recently been diagnosed with pancreatic cancer that had spread to other organs took daraxonrasib once a day alongside standard chemotherapy (gemcitabine and nab-paclitaxel).
According to the company’s figures, tumours shrank or disappeared in around 61% of patients and stopped growing in about 90%. In roughly 8%, or about one in 12, tumours could no longer be seen on CT scans. Half of the group went at least 12.8 months before their cancer worsened, and an estimated 76.6% were alive a year after starting treatment. Patients had been followed for a median of about 18 months.
Cancer Research UK described the findings as the biggest step forward for the disease in decades. Pancreatic cancer has the lowest survival rate of the common cancers in the UK, with around 11,500 diagnoses and 10,200 deaths a year, according to figures cited by the BBC.
Is it a cure?
Doctors are clear that it should not be described as one. Cancer that cannot be seen on a scan is not necessarily gone, and Cancer Research UK’s Dr Sam Godfrey told the BBC that it takes more time to know whether someone is truly cancer-free. The study was small, every participant received the drug (so there was no direct comparison group on chemotherapy alone), and the company itself cautions that early findings may not be repeated in larger studies. A big randomised phase 3 trial, called RASolute 303, is now testing the pill against chemotherapy in newly diagnosed patients.
Why isn’t daraxonrasib available on the NHS?
Every new medicine has to clear two separate UK hurdles. First, the Medicines and Healthcare products Regulatory Agency (MHRA) must grant a licence, deciding whether the drug’s benefits outweigh its risks. Then the National Institute for Health and Care Excellence (NICE) decides whether it is good enough value for the NHS in England to pay for.
In a written parliamentary answer in June, the Department of Health and Social Care said daraxonrasib was not licensed in the UK and was not on NICE’s work programme, and that NICE would look at it if the manufacturer applied to the MHRA. In its November update, Pancreatic Cancer UK said it hoped the company would submit the drug to the MHRA soon, and estimated the licensing and NICE process could take about a year once under way. We could not find any public confirmation that an MHRA application has been filed.
It is also worth separating the two groups of patients. The US approval in August and the EU approval this autumn cover people whose cancer has spread and who have already had treatment, based on a larger 500-patient trial in which median survival rose from 6.7 months on chemotherapy to 13.2 months on daraxonrasib. The new Barcelona results are about newly diagnosed patients, a use no regulator has approved yet.
Can UK patients get daraxonrasib now?
Only through research. Pancreatic Cancer UK says several UK trials of the drug, all carrying the RASolute name, are running, and that patients should talk to their oncology team about whether one might suit them. The charity also suggests asking about genomic testing, which can show whether a tumour carries a KRAS mutation; around nine in ten of the most common type of pancreatic cancer do. Its specialist nurses can answer questions on 0808 801 0707, although they cannot place anyone on a trial.
Like any cancer drug, daraxonrasib has side effects. US prescribing information lists rash, diarrhoea, mouth sores, nausea and fatigue among the most common, with rarer but serious problems involving the lungs and gut. Anyone affected should discuss the options with their own medical team rather than rely on headlines.
Sources
- BBC News: Massive hope for pancreatic cancer pill after trial saw tumours vanish
- Revolution Medicines: updated phase 1/2 data for RASONQUE (daraxonrasib) plus chemotherapy
- Pancreatic Cancer UK: Understanding KRAS inhibitors (updated November 2026)
- Written question 7440: Pancreatic cancer – daraxonrasib (answered 15 June 2026)
- European Medicines Agency: Rasonque (daraxonrasib)
- LBC: Daily pill leaves tumours undetectable in one in 12 pancreatic cancer patients

